Viking Therapeutics, Inc.
VKTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.20 | -0.27 | -0.53 | -0.70 |
| FCF Yield | -3.18% | -1.58% | -1.93% | -0.70% |
| EV / EBITDA | -28.94 | -39.40 | -48.13 | -96.58 |
| Quality | ||||
| ROIC | -13.81% | -9.36% | -6.54% | -5.25% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 1.04 | 0.72 | 1.15 | 0.88 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -99.75% | 10.07% | -67.83% | -41.98% |
| Safety | ||||
| Net Debt / EBITDA | 1.01 | 0.44 | 0.67 | 0.55 |
| Interest Coverage | 0.00 | -3,107.25 | 0.00 | -1,926.58 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -4,414.82 | 0.00 | 0.00 |